Imunon, Inc. (IMNN)

NCM – Цена в реальном времени. Валюта: USD

1.79

+0.07 (4.07%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

1.91

+0.12 (6.78%)

После закрытия: Jun 26, 2026, 7:56 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Imunon, Inc. (IMNN)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Imunon, Inc. (IMNN)

IMUNON Announces Up to $10 Million Cash Financing

Imunon, Inc. (IMNN) Q1 2026 Earnings Call Transcript

IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026

Imunon, Inc. (IMNN) Q4 2025 Earnings Call Transcript

IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study

IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer

Видео

No Data

Пресс-релизы

IMUNON Announces Up to $10 Million Cash Financing

IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study

IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer

Search stocks

Imunon, Inc. (IMNN)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Imunon, Inc. (IMNN)

IMUNON Announces Up to $10 Million Cash Financing

Imunon, Inc. (IMNN) Q1 2026 Earnings Call Transcript

IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026

Imunon, Inc. (IMNN) Q4 2025 Earnings Call Transcript

IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study

IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer

Видео

No Data

Пресс-релизы

IMUNON Announces Up to $10 Million Cash Financing

IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study

IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer